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cancer after failure of (neo) adjuvant anthracycline-based
therapy, relative to paclitaxel (T) monotherapy, in Australia.
Paclitaxel monotherapy is a treatment of choice in advanced,
anthracycline-resistant breast cancer in Australia. METHODS:
Economic evaluation was based on the global, randomised trial
of GT versus T (N = 529) (Albain et al, ASCO 2004). Median
survival for the intention-to-treat population was 18.5 months
(95% CI, 16.5 to 21.2 months) for the GT arm versus 15.8
months (95% CI, 14.4 to 17.4 months) for the T arm (hazard
ratio = 0.78 [95% CI, 0.63 to 0.96]. Higher toxicity in the com-
bination arm did not have a negative impact on quality of life
(Moinpour et al, ASCO 2004). Mean survival time for each
treatment arm was estimated from Kaplan-Meier survival curves.
Resource use (chemotherapy, administration, hospitalisation due
to adverse events [AEs], treatment emergent AEs) was applied as
per the trial and costed accordingly, using Australian dollars
(2004 value). Threshold of <$50,000 per life-year gained was
considered cost-effective. RESULTS: Mean cost per patient on
GT arm was $21,695 ($19,389 for chemotherapy, $1003 for
administration, and $1304 for AE management). Mean cost per
patient on T arm was $13,635 ($12,397 for chemotherapy, $567
for administration, and $670 for AE management). Mean sur-
vival gain for GT over T was 0.176 years. Cost per life-year
gained for GT was $45,799. CONCLUSION: This survival
beneﬁt is a highly patient-relevant outcome for advanced breast
cancer. This economic evaluation found that gemcitabine plus
paclitaxel offers an acceptable cost-effectiveness ratio and good
value-for-money for patients with advanced breast cancer in 
Australia.
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OBJECTIVES: Estimate the costs of care and outcomes associ-
ated with adjuvant, intravesical therapy (AIT)—either BCG or
chemotherapy—for non-invasive bladder cancer compared to no
AIT. METHODS: Subjects diagnosed with non-invasive transi-
tional cell carcinoma of the bladder between 1992 and 1999
were drawn from the SEER-Medicare dataset. We estimated the
effect of treatment on costs and outcomes within ﬁve risk groups
deﬁned by stage and grade of disease. We included subjects that
were at least 66 years old and who had fee-for-service coverage.
We estimated direct medical costs (for Medicare) using the
Kaplan-Meier sample average estimator. Using Cox models, we
estimated the effectiveness of AIT using three measures: survival
time, time to cystectomy (surgical removal of the bladder) and
time to repeat transurethral resection (TUR: surgical removal of
lesions in the bladder). The models adjusted for age, sex, race,
comorbidities and socioeconomic status. RESULTS: Subjects had
2 to 10 years of follow-up. A total of 13,658 subjects were
included: 2137 received AIT. Mean costs (2004 dollars) were
$53,834 for those that received AIT and $47,884 for those that
did not receive AIT. Difference in costs between treatment groups
was similar for the ﬁve risk groups. AIT reduced the risk of death
for subjects with stage 1, grade 3 or 4 tumors (hazard ratio: 0.82;
95% CI: 0.71 to 0.94). Survival was not statistically signiﬁcantly
different in other risk groups. AIT reduced the risk of repeat
TUR in each risk group. Conversely, AIT increased the risk of
cystectomy for subjects with low grade disease and carcinoma in
situ. CONCLUSIONS: AIT increased Medicare costs over 10
years by $5950. AIT reduced mortality for high risk subjects
only, reduced the risk of TUR for all risk groups and increased
the risk of cystectomy for low risk subjects. Residual confound-
ing may explain mixed ﬁndings.
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OBJECTIVES: A recent randomized trial compared granulocyte
colony-stimulating factor (G-CSF; ﬁlgrastim) to no G-CSF 
in elderly patients with aggressive NHL receiving CHOP
chemotherapy [Osby, 2003]. A cost-effectiveness analysis is pre-
sented comparing CHOP alone to CHOP + G-CSF. METHODS:
An economic model based on this trial compares the risk of neu-
tropenia, disease relapse, and 5-year survival among patients
receiving CHOP with or without G-CSF. Cost estimates were
derived from published literature and data from U.S. health
centers. Incremental cost-effectiveness ratios (ICERs) of $US/life
year saved (LYS) were estimated, and sensitivity analyses per-
formed. RESULTS: CHOP + G-CSF was associated with signif-
icantly fewer episodes of severe neutropenia (P < 0.001), FN (P
< 0.001), greater dose intensity (P < 0.05), fewer deaths (P =
0.04), and improved 5-year survival (P = 0.04). Based on ﬁve
years of followup, the life years averaged 2.93 years in the CHOP
alone group compared to 3.52 years in the CHOP + G-CSF arm.
Expected costs were $41,400 and $39,747 for the G-CSF and
control arms, respectively. Under baseline assumptions, the ICER
for G-CSF support was estimated at $2769/LYS. Sensitivity
analyses revealed G-CSF support to be cost saving across most
plausible values for baseline FN risk, relative risk reductions for
FN, infection-related mortality, and risks of disease relapse. G-
CSF support remained cost saving until the control risk for
disease relapse fell to <2%. Net cost savings were observed for
FN relative risk reductions >56%. CONCLUSIONS: A recent
clinical trial of G-CSF support demonstrated a reduction in neu-
tropenic complications and improved survival. Incorporation of
cost data into an economic model based on this trial demon-
strates that G-CSF support is within accepted limits for cost-
effectiveness across a broad range of assumptions.
PCN13
COST-EFFECTIVENESS ANALYSIS OF APREPITANT IN THE
PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND
VOMITING IN PATIENTS RECEIVING EITHER CISPLATIN-
BASED CHEMOTHERAPY REGIMENS OR MODERATELY
EMETOGENIC CHEMOTHERAPY
Annemans L1, Strens D1, Lox E2, Petit C2, Malonne H2
1HEDM-IMS Health, Brussels, Belgium, 2Merck Sharp & Dohme bv,
Brussels, Belgium
OBJECTIVES: Aprepitant is effective in preventing 
chemotherapy-induced nausea and vomiting (CINV), achieving
higher complete response (CR = no emesis and no rescue
therapy) compared to standard prevention, in patients receiving
either highly (HEC) or moderately emetogenic chemotherapy
(MEC) (absolute improvement = 11% and 13% respectively).
We assessed the cost-effectiveness of aprepitant based versus
standard prevention in these indications in Belgium.
METHODS: A decision analytical model was developed in MS
Excel. To estimate resource use, two approaches are used. The
ﬁrst is based on the preventive regimens applied in randomized
controlled trials comparing aprepitant based CINV prevention
